Skip to main content
Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
29.65
+1.31 (4.62%)
Mar 9, 2026, 4:00 PM EDT - Market closed

Viridian Therapeutics Revenue

In the year 2025, Viridian Therapeutics had annual revenue of $70.85M with 23,359.93% growth. Viridian Therapeutics had revenue of $132.00K in the quarter ending December 31, 2025, with 83.33% growth.

Revenue (ttm)
$70.85M
Revenue Growth
+23,359.93%
P/S Ratio
42.77
Revenue / Employee
$495,448
Employees
143
Market Cap
3.03B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202570.85M70.55M23,359.93%
Dec 31, 2024302.00K-12.00K-3.82%
Dec 31, 2023314.00K-1.46M-82.28%
Dec 31, 20221.77M-1.19M-40.20%
Dec 31, 20212.96M1.91M182.19%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Catalyst Pharmaceuticals 588.99M
Tarsus Pharmaceuticals 451.36M
Arcutis Biotherapeutics 376.07M
Arcus Biosciences 247.00M
IDEAYA Biosciences 218.71M
Beam Therapeutics 139.74M
Dianthus Therapeutics 3.08M
Revenue Rankings

VRDN News

More News